ReviewJPRAS open2025
Research progress of liposomal bupivacaine and its value in perioperative pain management.
Review in JPRAS open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Liposomal Bupivacaine for Postoperative Analgesia After Multilevel Posterior Lumbar Fusion Surgery: A Prospective Three-Arm Randomized Study.Drug design, development and therapy · 2026Trial
- The Emerging Role of Liposomal Bupivacaine in Erector Spinae Plane Blocks for Post-Operative Pain Management in Spine Surgeries: A Narrative Review.Clinical pharmacology : advances and applications · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In current pain management practices, multimodal analgesia strategies centered on regional nerve blocks, combined with low-dose opioids and adequate nonsteroidal anti-inflammatory drugs, are considered the standard approach. However, the short-lived effectiveness of conventional local anesthetics leads to inadequate postoperative pain management, which substantially diminishes patient comfort and satisfaction during recovery periods. Prolonging the duration of local anesthetics has become a core focus of regional anesthesia research, with liposomal bupivacaine gaining attention due to its ultra-long-acting properties. This article aims to systematically explore the mechanism of action, safety, potential adverse reactions, and clinical applications of liposomal bupivacaine in nerve blocks and surgical procedures, providing a scientific basis for optimizing clinical analgesia strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.